After a failed serelaxin trial, Novartis has to tear up sales estimates it hinted at in January, leaving Entresto to carry the load in heart failure—if it can…

Alexion’s CEO search is over. The Connecticut biotech, which bade its skipper farewell late last year, is bringing former Baxalta chief Ludwig Hantson into the…

Three years after a federal judge dismissed about 5,000 lawsuits by patients claiming Merck & Co.’s osteoporosis drug Fosamax was responsible for their…

Psoriasis is a visible skin condition, but to J&J that's only half the story. The company wants to tell the full story of psoriasis' impact.

#FierceMadness' DTC shootout narrows to eight this weekend as hope beating fear. Voting for Final Four begins today.

With the FDA's approval of Purdue and Shionogi's Symproic, there's now a third competitor prepping to jump into the opioid-induced constipation…

Eli Lilly CEO David A. Ricks today announced an $85 million expansion of Lilly diabetes med manufacturing operations in Indianapolis.

Eli Lilly suffered the failure of its long-anticipated Alzheimer’s compound solanezumab and faced falling demand for key blockbusters last year. Nevertheless,…

Pharma